Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque ex augue, fringilla non ultricies quis, tempus quis ligula. Nullam convallis orci et tellus tincidunt, vel pharetra odio bibendum.

 
 
kaveh.png

Kaveh Memari

Chief Executive Officer

Worked for the last 12 years in start-ups spinning out new technologies and products, raising significant private capital and expanding internationally.


Adrian Bennett

Chief Product Designer

With over 20 years experience in product development, Adrian has taken over 200 products  to market and won over a dozen awards across multiple consumer sectors.

Adrian.png

Ian.png

Ian Murison

NED – Product

Worked for over 20 years with Adrian in their industrial design agency Curventa shaping disruptive products for blue chip clients & start-ups.


Ross Reason

NED – Investor Representative

As an economist, accountant, and investor and fund manager, Ross bring seasoned financial expertise and represents shareholders on the board. He currently is a director at HgCapital LLP and the Cambridge University Endowment Fund.

Ross.png

David.png

David Lawson

Lead Scientist

A biochemist by background, David was responsible for the project management and submission of the worlds for medically regulated electronic cigarette which was approved in 2013 by the medicine regulator in the UK.  David has worked exclusively in the ENDS category for over 7 years and has acquired a wealth of knowledge in all areas of ENDS regulation. More recently, David has been responsible for establishing a world class consultancy team focusing on ENDs and pharmaceutical product development.  David also sat as a technical expert on 3 working groups contributing to the European Tobacco Products Directive (TPD) as well as sitting on the Technical Committee established for TPD.


Mark Dignum

Qualified Person

Mark has worked with pharmaceutical and medical device products for over 20 years and has been involved in ENDS for 7 years.  Mark was listed as the Quality Expert on the Nicadex / e-voke project and worked on the development, characterisation and registration of the product through to final approval.  Mark has a thorough understanding and appreciation  of the regulatory framework for a wide range of products over a wide range of territories. Mark has worked with regulators on ENDS and has significant experience in quality, characterisation and production standards.

Mark.png

Stuart.png

Stuart Fletcher

Advisor to Board

Stuart Fletcher was, until April 2016, Chief Executive Officer of Bupa, a role he held from March 2012. Bupa is a leading global health and care company with 32m customers in 190 countries and 84,000 employees around the world, principally in the UK, Australia, Spain, Poland, New Zealand and Chile, as well as Saudi Arabia, Hong Kong, India, Thailand and the USA. With no shareholders, it reinvests profits to provide more and better healthcare and fulfil its purpose: longer, healthier, happier lives. Before joining Bupa, Stuart spent 26 years in leadership positions with Diageo Plc. He was President of Diageo International between 2004-2011, having been President of Key Markets from 2000-2004. Stuart held a number of other senior general management and finance positions with Diageo including roles based in Japan, USA and Hong Kong. He previously held various finance roles with Procter & Gamble in the UK.  Stuart is a member of the Advisory Board of the Wellcome Trust Centre for Human Genetics at Oxford University. He is a Fellow of the Association of Chartered Certified Accountants(FCCA) and a Member of the Chartered Management Institute (MCMI).


Stephen “Smarshy” Marsh

Advisor to Product Team (Mechanical)

Stephen has been heading mechanical developments at B20 for more than three years, and previously been designing, developing and manufacturing inhalation devices for the pharmaceutical industry.   Significant projects include:

Medical Inhaler Device - Relenza Flu Drug (Glaxo, 2001) - Design of Medical Inhaler Device with Geared Indexing Mechanism comprising plastic Injection Moulded Components. (Production, 1m+ per year)

Medical Inhaler Device - Inhaled Insulin (Pfizer, 2006) - Technical Lead on Design and Development of medical Inhaler Device to provide Metered dose of Micronised Insulin. (Production  80m+ per year)

Medical Inhaler Device (Cambridge Consultants Ltd., 2010) - Design of a Medical Inhaler Device for entrainment of Micronised Drug into Inhaled Air Stream. Design of Powder Reservoir and method of dispensing from reservoir to inhalation chamber. (Production 1m+ per year)

Stephen.png